STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(e) of the Securities Exchange Act of 1934 
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  
   Townsend Adam J.  
   (Last)  (First)  (Middle)  
   C/O APELLIS PHARMACEUTICALS, INC.  
   100 FIFTH AVENUE, 3RD FLOOR  
   WALTHAM  MA  02451  
   (Street)  (City)  (State)  (Zip)  

2. Issuer Name and Ticker or Trading Symbol  
   Apellis Pharmaceuticals, Inc. [ APLS ]  

3. Date of Earliest Transaction (Month/Day/Year)  
   08/11/2022  

4. If Amendment, Date of Original Filed (Month/Day/Year)  
   08/11/2022  

5. Relationship of Reporting Person(s) to Issuer  
   (Check all applicable)  
   Director  X  
   10% Owner  
   Officer (give title below)  
   Other (specify below)  
   Chief Commercial Officer  

6. Individual or Joint/Group Filing (Check Applicable Line)  
   X Form filed by One Reporting Person  
   Form filed by More than One Reporting Person  

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>1. Title of Security (Instr. 3)</th>
<th>2. Transaction Date (Month/Day/Year)</th>
<th>3. Transaction Code (Instr. 8)</th>
<th>4. Securities Acquired (A) or Disposed Of (D) (Instr. 3 and 4)</th>
<th>5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</th>
<th>6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>7. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>08/11/2022</td>
<td>M(1)</td>
<td>A</td>
<td>$15,09</td>
<td>55,407</td>
<td>D</td>
</tr>
<tr>
<td>Common Stock</td>
<td>08/11/2022</td>
<td>S(1)</td>
<td>D</td>
<td>$67</td>
<td>42,907</td>
<td>D</td>
</tr>
</tbody>
</table>

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security  
   (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reportd Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
|-----------------|--------------------------------------------------------|------------------------------------|-------------------------------|------------------------------------------------------------------------------------------------|----------------------------------------------------------|--------------------------------------------------------------------------------------|----------------------------------|----------------------------------------------------------------------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| Stock Option (Right to Buy) | $15.09  
   (High to Buy) | 08/11/2022 | M(1)               | 12,500                      | (2)    | 11/15/2028  
   Common Stock | 12,500 | $0   | 340,000 | D |

Explanation of Responses:

1. This is a scheduled exercise and sale form an established 10b5-1 plan.  
2. This represents a stock option granted 11/16/2018 that vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.  
3. This is a scheduled exercise and sale form an established 10b5-1 plan.  

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.  
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).  
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.  
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.  

/s/ David Watson, attorney-in-fact for Adam Townsend  
08/12/2022  
** Signature of Reporting Person  
Date